Relief For Migraine as England’s NICE Reverses Ajovy Knockback
Executive Summary
The latest decision by the health technology assessment body means up to 10,000 people will be able to receive Teva’s drug on the National Health Service. Ajovy is the first anti-CGRP migraine therapy recommended by NICE, whose decision will also be of interest to CGRP inhibitor rivals including Novartis, Lilly and Lundbeck.
You may also be interested in...
Netherlands Gives Funding Nod To CGRP Inhibitors For Chronic Migraines
The Dutch health technology appraisal body, ZIN, said Novartis’ Aimovig should be reimbursed for the treatment of chronic migraine after initially advising against it.
Keeping Track: Two Novel Migraine Drugs Highlight Busy Week For US FDA Approvals
The latest drug development news and highlights from our US FDA Performance Tracker.
EMA Probe Finds No Link Between GLP-1s And Suicidal Thoughts & Actions
After reviewing the evidence from non-clinical studies, clinical trials, post-marketing surveillance data and other studies, the European Medicines Agency said there was no need to update the product information for 11 diabetes and weight management drugs.